NEW BRUNSWICK, N.J. - Johnson & Johnson says it plans to submit more than 10 new treatments to regulators for approval and 25 applications for additional uses of approved drugs by 2017.
The New Brunswick, N.J., company says its pipeline of drugs in late-stage clinical development include a potential hepatitis C treatment being reviewed by regulars, a version of the anti-psychotic Invega designed to last three months and new vaccines for flu, rabies and polio.
J&J makes prescription drugs, consumer health products and medical devices.
It says its pharmaceuticals segment has launched 11 new products since 2009. They made up 17 percent of total pharmaceutical sales last year, which is up from 9 percent in 2011. These products include the blood thinner Xarelto, Invega and J&J's first diabetes treatment, Invokana.